Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 ...

San Antonio’s H-E-B and other major retailers have teamed up to wage legal battles on both coasts against pharmaceutical companies for allegedly monopolizing the market for certain prescription drugs.

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

NVAX), a biotechnology company with a current market capitalization of $1.03 billion and annual revenue of $682 million, has renegotiated the terms of its collaboration with Takeda Pharmaceutical ...